b-style holdings,Inc.
302A
FORCIA,Inc.
304A
visumo Inc.
303A
Kioxia Holdings
285A
GVA TECH,Inc.
298A
JP Stock MarketDetailed Quotes
4883 Modalis Therapeutics
- 100
- 00.00%
20min DelayMarket to Open Dec 20 15:30 JST
6.94BMarket Cap-1.29P/E (Static)
0High0Low0Volume0Open100Pre Close0.00Turnover20352wk High0.00%Turnover Ratio69.40MShares6252wk Low-64.98EPS TTM6.22BFloat Cap4070Historical HighLossP/E (Static)62.16MShs Float62Historical Low-77.24EPS LYR0.00%Amplitude--Dividend TTM5.09P/B100Lot Size--Div YieldTTM
About Modalis Therapeutics Company
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.
Company Profile
Symbol4883
Company NameModalis Therapeutics
Founded2016-01-14
MarketTSE Growth
Employees37
Fiscal Year Ends12-31
Address16-5 Nihombashi-Kabuto-cho Chuo-ku
Zip Code103-0023
Phone03-6822-4584
Websitemodalistx.com
Company Executives
-
Name
- Position
- Salary
-
Haruhiko Morita
- Representative Director and President
- --
-
Toshio Furuta
- Independent Director
- --
-
Teruhisa Tashima
- Independent Director
- --
-
Miyuki Shimane
- Independent Director
- --
-
Joseph McCracken
- Independent Director
- --
-
Hideki Takeda
- Independent Director
- --